An update on the available and emerging pharmacotherapy for adults with testosterone deficiency available in the USA

References

• Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996 Dec;81(12):4358–4365.
   PubMed Web of Science ®Google Scholar
• Jockenhovel F, Vogel E, Reinhardt W, et al. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res. 1997 Jul 28;2(7):293–298.
   PubMedGoogle Scholar
• Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979 Jun;48(6):955–958.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug;85(8):2670–2677. .
   PubMed Web of Science ®Google Scholar
• Clavijo RI, Ramasamy R. Testosterone replacement should be given to men with erectile dysfunction: pro. J Urol. 2017 Feb;197(2):284.
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1987 Mar;106(3):354–361.
   PubMed Web of Science ®Google Scholar
• Carnegie C. Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev Urol. 2004;6(Suppl 6):S3–8.
   PubMedGoogle Scholar
• Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012 May;97(5):1508–1516.
   PubMed Web of Science ®Google Scholar
• Lokeshwar SD, Patel P, Fantus RJ, et al. Decline in serum testosterone levels among adolescent and young adult men in the USA. Eur Urol Focus. 2020 Feb 18. DOI:https://doi.org/10.1016/j.euf.2020.02.006.
   Google Scholar
• Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018 Aug;200(2):423–432.
   PubMed Web of Science ®Google Scholar
• Masterson JM, Cohen J, Blachman-Braun R, et al. Pre-treatment estradiol does not predict testosterone response to clomiphene citrate. Transl Androl Urol. 2020 Apr;9(2):609–613. .
   PubMed Web of Science ®Google Scholar
• Bibliography of the current world literature on AIDS. AIDS. 1988 Aug;2(4):A31–41.
   PubMed Web of Science ®Google Scholar
• Shoshany O, Abhyankar N, Mufarreh N, et al. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men. Fertil Steril. 2017 Mar;107(3):589–594.
   PubMed Web of Science ®Google Scholar
• Lima TFN, Rakitina E, Blachman-Braun R, et al. Evaluation of a serum 17-hydroxyprogesterone as predictor of semen parameter(s) improvement in men undergoing medical treatment for infertility. Can Urol Assoc J. 2020 Dec 15;15(7). https://doi.org/10.5489/cuaj.6846.
   Google Scholar
• Lima TFN, Patel P, Blachman-Braun R, et al. Serum 17-hydroxyprogesterone is a potential biomarker for evaluating intratesticular testosterone. J Urol. 2020 Sep;204(3):551–556.
   PubMed Web of Science ®Google Scholar
• Patel A, Patel P, Bitran J, et al. Can serum 17-hydroxyprogesterone and insulin-like factor 3 be used as a marker for evaluation of intratesticular testosterone? Transl Androl Urol. 2019 Mar;8(Suppl 1):S58–S63.
   PubMed Web of Science ®Google Scholar
• Southwell D, Barry BW. Penetration enhancers for human skin: mode of action of 2-pyrrolidone and dimethylformamide on partition and diffusion of model compounds water, n-alcohols, and caffeine. J Invest Dermatol. 1983 Jun;80(6):507–514.
   PubMed Web of Science ®Google Scholar
• Abadilla KA, Dobs AS. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs. 2012 Aug 20;72(12):1591–1603.
   PubMed Web of Science ®Google Scholar
• ANDRODERM® [FDA Label]. North Chicago (IL): Abbvie; 2011 Oct.
   Google Scholar
• Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999 Oct;84(10):3469–3478.
   PubMed Web of Science ®Google Scholar
• ANDROGEL®, 1% [FDA label]. North Chicago (IL): AbbVie; 2013 May.
   Google Scholar
• Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J Clin Endocrinol Metab. 2000 Mar;85(3):964–969. .
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000 Dec;85(12):4500–4510. .
   PubMed Web of Science ®Google Scholar
• ANDROGEL®, 162% [package insert]. North Chicago (IL): AbbVie; 2015 May.
   Google Scholar
• Liu J, Jiang Z, Zhang S, et al. Biodegradation, biocompatibility, and drug delivery in poly(omega-pentadecalactone-co-p-dioxanone) copolyesters. Biomaterials. 2011 Sep;32(27):6646–6654.
   PubMed Web of Science ®Google Scholar
• TESTIM® [FDA label]. Malvern (PA): AuxiliumPharmaceuticals Inc; 2016 Oct.
   Google Scholar
• Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003 Jun;88(6):2673–2681. .
   PubMed Web of Science ®Google Scholar
• FORTESTA® [FDA label]. Malvern (PA): EndoPharmaceuticals; 2017 Jul.
   Google Scholar
• Dobs AS, McGettigan J, Norwood P, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl. 2012 Jul-Aug;33(4):601–607.
   PubMedGoogle Scholar
• VOGELXO® [FDA label]. Maple Grove (MN): Upsher-Smith Laboratories; 2016 Sep.
   Google Scholar
• Arver S, Stief C, De La Rosette J, et al. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology. 2018 May;6(3):396–407.
   PubMed Web of Science ®Google Scholar
• AXIRON® [FDA Label]. Indianapolis (IN): Eli Lilly; 2017 Feb.
   Google Scholar
• Wang C, Ilani N, Arver S, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf). 2011 Dec;75(6):836–843.
   PubMed Web of Science ®Google Scholar
• STRIANT® [Package insert]. Malvern (PA): EndoPharmaceuticals LLC; 2015 May.
   Google Scholar
• Wang C, Swerdloff R, Kipnes M, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004 Aug;89(8):3821–3829.
   PubMed Web of Science ®Google Scholar
• Korbonits M, Slawik M, Cullen D, et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab. 2004 May;89(5):2039–2043.
   PubMed Web of Science ®Google Scholar
• Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012 Jul;110(2):162–169.
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Keenan DM, Liu PY, et al. Kinetics of removal of intravenous testosterone pulses in normal men. Eur J Endocrinol. 2010 Apr;162(4):787–794.
   PubMed Web of Science ®Google Scholar
• Edelstein D, Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother. 2010 Aug;11(12):2095–2106.
   PubMed Web of Science ®Google Scholar
• Depo-Testosterone© [FDA label]. New York (NY): Pharmacia and Upjohn Company; 2018 Jul.
   Google Scholar
• Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018Jan6;6(1):77–85.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715–1744.
   PubMed Web of Science ®Google Scholar
• Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril. 1987 Jun;47(6):1004–1009.
   PubMed Web of Science ®Google Scholar
• Testosterone enanthate [FDA label]. Malvern (PA: Endo Pharmaceuticals; 2016 Oct.
   Google Scholar
• Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980 Dec;51(6):1335–1339.
   PubMed Web of Science ®Google Scholar
• XYOSTED® [FDA label]. Malvern (PA): AntaresPharma Inc; 2019 Sep.
   Google Scholar
• Kaminetsky JC, McCullough A, Hwang K, et al. A 52-week study of dose adjusted subcutaneous testosterone enanthate in oil self-administered via disposable auto-injector. J Urol. 2019 Mar;201(3):587–594.
   PubMed Web of Science ®Google Scholar
• Arora S, Moclair B, Murphy K, et al. Summative usability evaluation of the SCTE-AI device: a novel prefilled autoinjector for subcutaneous testosterone administration. J Sex Med. 2018 Dec;15(12):1707–1715.
   PubMed Web of Science ®Google Scholar
• AVEED© [FDA label]. Malvern (PA): EndoPharmaceuticals; 2013 Mar.
   Google Scholar
• Pastuszak AW, Hu Y, Freid JD. Occurrence of pulmonary oil microembolism after testosterone undecanoate injection: a postmarketing safety analysis. Sex Med. 2020 Jun;8(2):237–242.
   PubMed Web of Science ®Google Scholar
• Wang C, Harnett M, Dobs AS, et al. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl. 2010 Sep-Oct;31(5):457–465.
   PubMedGoogle Scholar
• Zhang GY, Gu YQ, Wang XH, et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl. 1998 Nov-Dec;19(6):761–768.
   PubMedGoogle Scholar
• Bishop PM, Folley SJ. Absorption of hormone implants in man. Lancet. 1951 Aug 11;2(6676):229–232.
   PubMed Web of Science ®Google Scholar
• TESTOPEL® [package insert]. Malvern (PA): EndoPharmaceuticals Inc; 2015 May.
   Google Scholar
• McCullough AA. Review of testosterone pellets in the treatment of hypogonadism. Curr Sex Health Rep. 2014;6(4):265–269.
   PubMedGoogle Scholar
• Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990 Jul;71(1):216–222.
   PubMed Web of Science ®Google Scholar
• Handelsman DJ, Mackey MA, Howe C, et al. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf). 1997 Sep;47(3):311–316.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [Internet]. Miami (FL): National Library of Medicine (US). 2020 August 21. Identifier NCT04523480, TESTOPEL ® vs. Generic Testosterone Pellets. Available from: https://ClinicalTrials.gov/show/NCT04523480
   Google Scholar
• NATESTO™ [FDA label]. Mississauga (ON): AcerusPharmaceuticals; 2014 May.
   Google Scholar
• Mattern C, Hoffmann C, Morley JE, et al. Testosterone supplementation for hypogonadal men by the nasal route. Aging Male. 2008 Dec;11(4):171–178.
   PubMed Web of Science ®Google Scholar
• Rogol AD, Tkachenko N, Bryson N. Natesto, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016 Jan;4(1):46–54.
   PubMed Web of Science ®Google Scholar
• Masterson T, Molina M, Ibrahim E, et al. Natesto effects on reproductive hormones and semen parameters: results from an ongoing single-center, investigator-initiated phase IV clinical trial. Eur Urol Focus. 2018 Apr;4(3):333–335.
   PubMedGoogle Scholar
• Daggett PR, Wheeler MJ, Nabarro JD. Oral testosterone, a reappraisal. Horm Res. 1978;9(3):121–129.
   PubMedGoogle Scholar
• Westaby D, Ogle SJ, Paradinas FJ, et al. Liver damage from long-term methyltestosterone. Lancet. 1977 Aug 6;2(8032):262–263.
   PubMed Web of Science ®Google Scholar
• Delorimier AA, Gordan GS, Lowe RC, et al. Methyltestosterone, related steroids, and liver function. Arch Intern Med. 1965 Aug;116(2):289–294.
   PubMedGoogle Scholar
• Nieschlag E, Mauss J, Coert A, et al. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh). 1975 Jun;79(2):366–374.
   PubMedGoogle Scholar
• Skakkebaek NE, Bancroft J, Davidson DW, et al. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf). 1981 Jan;14(1):49–61.
   PubMed Web of Science ®Google Scholar
• Bagchus WM, Hust R, Maris F, et al. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy. 2003 Mar;23(3):319–325.
   PubMed Web of Science ®Google Scholar
• Schnabel PG, Bagchus W, Lass H, et al. The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf). 2007 Apr;66(4):579–585.
   PubMed Web of Science ®Google Scholar
• Yin A, Alfadhli E, Htun M, et al. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men. J Androl. 2012 Nov-Dec;33(6):1282–1290.
   PubMedGoogle Scholar
• Swerdloff RS, Wang C, White WB, et al. A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men. J Clin Endocrinol Metab. 2020 Aug 1;105(8):2515–2531.
   Web of Science ®Google Scholar
• Swerdloff RS, Dudley RE. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther Adv Urol. 2020 Jan-Dec;12:1756287220937232.
   Web of Science ®Google Scholar
• JATENZO® [FDA label]. ClarusTherapeutics Inc: Northbrook (IL). Mar 2019
   Google Scholar
• Gooren L. Advances in testosterone replacement therapy. Front Horm Res. 2009;37:32–51.
   PubMed Web of Science ®Google Scholar
• Skogastierna C, Hotzen M, Rane A, et al. A supraphysiological dose of testosterone induces nitric oxide production and oxidative stress. Eur J Prev Cardiol. 2014 Aug;21(8):1049–1054.
   PubMed Web of Science ®Google Scholar
• Ory J, White JT, Moore J, et al. Canadian trends in testosterone therapy. Can Urol Assoc J. 2020 Nov 17;15(6). DOI:https://doi.org/10.5489/cuaj.6892.
   Google Scholar
• Arora H, Zuttion M, Nahar B, et al. Subcutaneous Leydig stem cell autograft: a promising strategy to increase serum testosterone. Stem Cells Transl Med. 2019 Jan;8(1):58–65.
   PubMed Web of Science ®Google Scholar
• Zang ZJ, Wang J, Chen Z, et al. Transplantation of CD51(+) stem leydig cells: a new strategy for the treatment of testosterone deficiency. Stem Cells. 2017 May;35(5):1222–1232.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Masterson TA, Best JC, et al. Effect of Natesto on reproductive hormones, semen parameters and hypogonadal symptoms: a single center, open label, single arm trial. J Urol. 2020 Sep;204(3):557–563. .
   PubMed Web of Science ®Google Scholar